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CHAPTER I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
The bovine alveolar macrophage (BAM) plays an important role in the 
primary line of defense against extraneous microorganisms such as those 
involved in the bovine respiratory disease (BRD) complex. Prophylactic 
and therapeutic properties interferon (IFN) have been considered for 
control of BRD. IFNs have been reported to have numerous effects on the 
bovine immune system including functional alterations of.BAM. Response 
of murine macrophages to IFN has been monitored by assaying 2',5'-oligo-
adenylate synthetase activity (2',5'-0AS). 2',5'-0AS, one of the enzymes 
induced by IFN, has been shown to have antiviral and immunomodulatory 
effects on murine macrophages. The 2' ,5 '-OAS assay is used to measure 
cellular response to IFN and has been reported to be more sensitive, 
rapid, and reliable than direct assay of serum IFN levels. For the 
reasons cited above, a decision was made to study the biological 
response of BAM to rBoiFN-al by assay of 2',5'-0AS activity in vitro as 
well as in vivo and viral yield reduction in vitro to gain better under-
standing of the effects of IFN on the bovine immune system and the 
mechanism of IFN action on BAM. 
BOVINE RESPIRATORY DISEASE 
Bovine respiratory diseases represent a disease complex involving 
stressors and viruses acting separately or together. The result of these 
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interactions is suppression of lung defense mechanisms which leads to 
predisposition to bacterial pneumonia (52). BRD has been divided into 
three clinical entities: enzootic pneumonia of calves, atypical inter-
stitial pneumonia, and shipping fever complex (38). Enzootic pneumonia 
of calves is generally an infectious disease occurring mainly in housed 
calves, whereas, atypical interstitial pneumonia is a noninfectious 
disease of adult cattle (71). Shipping fever encompasses the acute pneu-
monic conditions of cattle that involve an undetermined mul tifac to rial 
etiology (38, 72) and are connnonly associated with Pasteurella haemo-
lytica. 
BRD is responsible for major economic losses to cattle producers 
each year. Losses are due not only to death but also to treatment costs, 
preventive measures, and decreased production (72). Jensen et al. (27) 
reported respiratory tract diseases were responsible for 75% of illness 
and 64% of deaths in a survey of 407,000 yearling feedlot cattle over a 
one year period. Lillie (38) estimated from 40 to 80% of all cattle 
disease involves the respiratory system, and in Canada alone losses to 
the cattle industry run into millions of dollars annually. 
Viruses most often associated with the infectious etiology of BRD 
include bovine herpesvirus-! (BHV-1), bovine viral diarrhea virus 
(BVD), parainfluenza-3 virus (PI-3V), bovine respiratory syncytial virus 
(BRSV), bovine herpesvirus-4 (BHV-4), bovine adenoviruses ( BAV), bovine 
rhinoviruses, bovine enteroviruses, reoviruses, and malignant catarrhal 
fever virus (MCF) (48). Severe respiratory dis ease may result due to 
increased susceptibility to bacterial infection of the respiratory 
tract. Secondary bacterial infections are predominantly by Pasteurella 
haemolytica or Pasteurella multocida (17). The viruses can infect an 
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animal, alter host defenses, and cause tissue damage. The damaged tissue 
provides a favorable environment for enhanced bacterial colonization, 
growth, and microcolony formation. The virus alone or in combination 
with bacteria, can also initiate the inflammatory process contributing 
damage to the respiratory system. Viral-bacterial synergistic interac-
tions in respiratory infections have been extensively reviewed (1). 
Challenge experiments provide evidence that viruses play an impor-
tant role in predisposition to bacterial pneumonia. Jericho and Langford 
(29) produced pneumonia in calves exposed first to an aerosol of BHV-1 
and second to an aero so 1 of P. haemolytica. An interval of at least 
four days between the virus and bacteria aerosolization was required to 
produce pneumonia. Excessive purulent pneumonia was produced in calves 
exposed to aerosols of PI-3V followed by challenge with aerosols of P. 
haemolytica three to ten days after virus exposure (28). Corstvet and 
Panciera (11) observed clinical signs of elevated temperature and respi-
ratory distress in calves exposed to aerosols of P. haemolytica 12 days 
after intratracheal inoculation of BVD. 
The BRD viruses are responsible for a combination of activities 
affecting the antiviral defense mechanisms of the lung. These activities 
include: impairment of mucocillary clearance; suppression of phagocytic 
cell function; and interference with lymphocyte function (1). BAM are 
permissive in culture for BHV-1 (16,62), BVD, PI-3V, and BRSV (62). 
Infection of BAM with PI-3V reduces their cytotoxic activity (45). BHV-1 
infected BAM have reduced Fe receptors, Fe mediated phagocytosis, com-
plement (C3b) receptor activity, and participation in antibody-dependent 
cell cytotoxicity (15). Bielefeldt, Ohmann, and Babiuk (7) reported 
depressed chemotaxis of polymorphonuclear (PMN) neutrophils and depres-
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sed natural cytotoxicity and mitogen response in peripheral blood leuko-
cytes (PBL) of cattle with experimentally induced fibrinous pneumonia. 
In addition, PMN superoxide anion production was transiently increased 
and interleukin-2 (IL-2) production was slightly decreased in these 
cattle. 
The alveolar macrophage (AM) is considered to play an integral part 
in the primary defense of the lung in face of viral and/or bacterial 
invasion (22). Phagocytosis by BAMs is important in the nonspecific 
primary line of defense against BRD (69). AMs aid in the specific immune 
response by processing and presenting antigen to T-lymphocytes and by 
releasing chemotactic agents which can enhance the immune response (33). 
Resulting enhanced bacterial growth due to viral alteration of lung 
defense mechanisms, as 1.n altered BAM function, supports the need for 
control of the viruses. 
control of BRD is IFN. 
One substance that has potential value for 
INTERFERON 
Interferon was discovered and named by Isaacs and Lindernnann in 
1957 in an experiment in which allantoic membrane pieces, pre-exposed to 
inactivated influenza virus, released a substance capable of protecting 
fresh pieces of membrane against homo- or heterotypic viruses (25). 
Interferons are (glyco)proteins produced in virus infected cells or in 
cells stimulated by other interferon-inducing agents. There are three 
types of IFN, alpha (IFN-a), beta (IFN-B), and gamma (IFN-Y), varying in 
their site of production and physicochemical characteristics (30). IFN-a 
is produced mainly in leukocytes, IFN- f3 is predominantly produced in 
fibroblasts, and IFN-y is produced by stimulated antigen-specific T-
5 
lymphocytes and is also known as class II or immune IFN (30). The bovine 
IFN(BoiFN) system consists of two classes of BoiFN-a, class 1 (BoiFN-a1) 
containing 10 - 12 subtypes and class 2 (BoiFN-a,Z) containing 15 - 20 
subtypes (9). There is one class of BoiFN-S with five subtypes and only 
one class and type of BoiFN- Y. 
There are three types of IFN production. Type I IFN production is 
due to the interaction of an IFN-producing cell and an inducer. This 
interaction is considered the classical induction of IFN and involves 
inducers of varying strength including: inducers containing nucleic 
acid; RNA and DNA animal virus; double-stranded RNA of normal cells; 
synthetic double-stranded RNA; unicellular agents; microbial and cellu-
lar products; synthetic chemical compounds; and low molecular weight 
compounds. Type II IFN production occurs in lymphocytes activated by 
cell-membrane active substances or by immune induction. Type III produc-
tion of IFN occurs spontaneously in normal or abnormal cells without 
obvious induction (24). 
Several in vitro and in vivo experiments on IFN induction by various 
inducers have been performed in the bovine system. IFN production was 
induced in fetal bovine kidney cell cultures infected with unirrad iated 
and an irradiated strain of PI-3V (50). High levels of circulating 
interferons were also induced in calves intravenously administered with 
BHV-1 virus (49). Fulton and Rosenquist (20) reported increased IFN 
concentrations in cultures of bovine fetal spleen cells, alveolar macro-
phages from adult cattle, and adult PBL in suspension which were treated 
with BHV-1 virus. They also demonstrated IFN production in bovine PBL 
treated with phytohemagglutinin (PHA). High serum IFN titers have also 
been detected in the early stage of infection in calves infected with an 
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aerosol of BRSV (14). Letchworth and Carmichael (37) reported IFN 
production in vitro by bovine peripheral blood monocytes in response to 
bovine herpesvirus-2 (BHV-2). In addition to viral IFN inducers, other 
investigators have shown increased IFN production in the bovine due to 
synthetic and/or natural dsRNA treatment in vitro of bovine cells or 1n 
vivo treatment of calves (34,47,51). 
Interferons are responsible for antiproliferative, immunomodula-
tory, and antiviral effects in the bovine as well as in other animals. 
The anti proliferative effects of Bo IFN in the bovine system have not 
received as much attention as antiviral and innnunomodulatory effects. 
Czarniecki et al. (13) reported on IFN-induced inhibition of cell growth 
in MDBK cell cultures. In their study, MDBK cell cultures were treated 
with BoiFN-a1, B 2, y, and human interferon alpha 2 (HuiFN-a2 ), and then 
observed seven days later for viable cell numbers. BoiFN-Y exhibited the 
greatest anti proliferative activity of the IFNs tested. There remain 
unknown aspects of the antiproliferative effects of IFN in the bovine. 
However, the focus of attention on IFN in the bovine will probably 
remain on the antiviral and innnunomodulatory functions. These two func-
tions relate more to the potential prophylactic and therapeutic use of 
IFN in BRD. 
Both the increased availab i1 ity of recombinant DNA-derived Bo IFN, 
and the conflicting in vitro and in vivo results on the antiviral activ-
ity of IFN in cattle, have stimulated interest in the immunomodulatory 
effects of IFN in the bovine. Most experiments on bovine innnunomodula-
tion have been performed in vitro, but limited in vivo studies have been 
conducted to investigate consistency with in vitro results. The innnune 
cells most often associated with primary lung defense are alveolar 
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macrophages, monocytes, and polymorphonuclear neutrophil s (43). These 
cells are mainly involved with the nonspecific cell-mediated immune 
response in reference to primary lung defense. Treatment of these cells 
with BoiFN-a.l has the following effects: 1) increased bacterial uptake 
by all three cells; 2) increased Fe receptors on alveolar macrophages; 
3) migration inhibition of monocytes and polymorphonuclear granulocytes; 
and 4) decreased lysozyme synthesis and/or increased secretion, 
increased hydrogen peroxide production, and decreased superoxide anion 
release by alveolar macrophages and polymorphonuclear granulocytes (5). 
BoiFN-y has even a greater effect on the leukocyte function than BoiFN-a. 
(4). 
Bo IFNs also modulate the natural cell-mediated cytotoxicity (NC) of 
the bovine. Bielefeldt, Ohmann, and Babiuk (6) reported in vitro and in 
vivo increased NC activity in healthy cattle. Lymphocyte proliferation 
ws suppressed 24 hours after PBL were treated in vitro with BoiFN-a. and 
- y (4). Such suppression was reversible by addition of exogenous IL-2 
and was due to BoiFN induction of suppressor cells (4). 
In vitro and in vivo Bo IFN-y treatment of BAMs enhanced major 
histocompatibility complex class II (Mhc class II) (Ia) antigen expres-
sion (8). However, in vivo, but not in vitro, class II antigen expres-
sion was enhanced in BAM of qeal thy cattle treated with BoiFN-a.1. BAM 
class II antigen expression is involved in antigen presentation to class 
II restricted antigen-specific T-lymphocytes. 
Initial studies on BoiFN dealt mainly with antiviral effects. Numer-
ous in vitro and some in vivo studies have been performed which examined 
antiviral activities of BoiFN against BRD viruses (2,3,12,18,19,21,63). 
All three types of BoiFN (a, S, andy) have exhibited antiviral activity 
8. 
to a certain degree (9). Sensitivity of viruses to IFN-induced viral 
inhibition varies (13,18,19,21). Of the three most commonly isolated BRD 
associated viruses (BHV-1, PI-3V, and BVD), BHV-1 is the least sensitive 
to the antiviral effects of IFN (13, 18, 21). Bo IFN-0'. and Bo IFN-13 have 
greater antiviral activity than BoiFN-Y; however, BoiFN-Y has the great-
est antiproliferative activity (13). 
Varied viral sensitivity and the various roles of the three BoiFNs 
may explain the difference in results of some in vitro and in vivo BoiFN 
studies. Calves treated with an aerosol or intramuscular injection of 
BoiFN-0'.1 48 hours prior to challenge with BHV-1 were less susceptible to 
a subsequent !· haemo1ytica challenge than calves that did not receive 
IFN (2,3). Decreased severity of clinical illness was not attributed to 
direct antiviral effects of BoiFN-0'.1. Instead, alterations in leukocyte 
functions were suggested to be responsible for the reduced severity of 
clinical illness (2). 
Viral induced BoiFN has also been reported to protect against sub-
sequent challenge exposure. Intranasal inoculation of calves with a 
BHV-1 vaccinal strain provided protection against challenge exposure 
with PI-3V (12). The mean PI-3V titers in nasal secretions were reduced 
in BHV-1 virus-inoculated calves as compared to control calves. In addi-
tion, virus excretion was not detected in PI-3V low dose (10 5• 3 TCID 50 ) 
challenged BHV-1 inoculated calves as compared to control calves. 
2',5'-0LIGOADENYLATE SYNTHETASE 
IFN is responsible for the production of several substances in a 
cell. Two of the most investigated are 2',5'-oligoadenylate synthetase 
(2',5'-0AS) and protein kinase (58). The current investigations are 
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focused on 2',5'-0AS. Kerr et al. (32) published the initial report of 
2',5'-0AS in 1977. All three types of IFN are capable of inducing 2',5'-
0AS (30). IFN induces the dsRNA dependent 2',5'-0AS enzyme which poly-
merizes ATP into a series of 2 1 ,5 '-phosphodiester bond linked oligonu-
cleotides (31). Nanomolar concentrations of these oligoadenylates 
(2', 5 '-A) activate a 2 1 ,5 '-A dependent latent endoribonuclease (56) 
which cleaves mRNA and rRNA resulting in inhibition of mRNA translation. 
Inhibition of viral mRNA translation is one of the mechanisms for the 
antiviral state observed in IFN treated cells. 2 1 ,5'-A is also produced 
in uninfected cells which are treated with IFN (10,35,59,61). Increased 
2',5'-0AS activity also occur during cell maturation and differentiation 
which suggests a possible role in controlling these cellular processes 
(26,60). The majority of investigations on the role of 2 1 ,5 1 -0AS, 
including its value as a marker for IFN induction and acute viral infec-
tions, have been performed in the human and murine systems. 
Schattner et al. (55) reported increased 2', 5 1-0AS activity 1n 
mononuclear cells and granulocytes of human patients given intramuscular 
injections of IFN-a. The increased enzyme levels remained elevated for 
at least 24 hours after IFN injection compared to serum IFN levels which 
decreased by 24 hours. Merritt et al. (42) observed a similar response 
in 2',5'-0AS levels of PBML cells from human patients injected with 
IFN-o:. In addition, Merritt et al. (41) found the magnitude and persis-
tence of the enzyme response to be a function of IFN dose. Enzyme activ-
ity was not related to the duration of treatment, number of injections, 
or the route of administration. IFN assays measuring antiviral activity 
are more time consuming and less sensitive than 2 1 ,5'-0AS assay (41,53). 
The assay of 2 1 ,5 1 -0AS in human peripheral white blood cells to monitor 
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IFN therapy has been suggested. Assay of 2 1 ,5 1 -0AS in peripheral blood 
mononuclear leukocyte (PBML) cells of patients has also been suggested 
as a diagnostic aid for patients with acute viral diseases and autoim-
mune diseases (53). PBML cells of patients receiving intramuscular and 
intravenous injections of HuiFN- a2a exhibited a parallel response of 
increased vesicular stomatitis virus (VSV) yield reduction and 2 1 ,5 1-0AS 
induction (70). Both responses were related to HuiFN-a2a dose. Three 
different investigations reported varied baseline 2 1 ,5 1-0AS concentra-
tions among the patients tested (42,53,55,70). 
Results similar to those ~n the human 2 1 ,5 1-0AS system have been 
reported for the murine system. VSV or Sindbis virus (SBV) infection of 
mice elicited a4- 7 fold increase in 2 1 ,5 1-0AS (54). Enzyme activity 
in murine PBML cells remained elevated for approximately one week before 
returning to baseline levels. Although 2 1 ,5 1-0AS activity was similar in 
the mice infected with one or the other virus, the changes in serum IFN 
levels varied between the two viruses. These findings suggest assay of 
2 1 ,5 1 -0AS for detection of viral infections and/or induction of endo-
genous interferon. Mice injected with antibody to mouse IFN-a/(3 had 
decreased 2 1 ,5 1 -0AS concentrations in resident peritoneal macrophages 
(23) 0 Decreased enzyme levels render macrophages permissive for VSV. 
Peritoneal macrophages from 1-week old mice had lower basal enzyme 
levels than 4 to 8-week old mice and were more permissive to VSV infec-
tion. However, peritoneal macrophages from 4 to 6-month old mice became 
increasingly permissive to VSV (23). Gresser et al. (23) reported an 
inverse correlation between 2 1 ,5 1 -0AS in the peritoneal macrophages and 
their permissiveness to VSV. Murine peritoneal macrophages, cultured in 
vitro for 3 to 5 days, became permissive to VSV and encephalomyocarditis 
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virus (EMCV) (46). The loss of the antiviral state paralleled a signif-
icant decrease in intracellular. 2 1 ,5 1-0AS activity. · Vogel and Fertsch 
(66) recently reported low levels of 2 1 ,5 1 -0AS and increased suscepti-
bility to viral infection in macrophages of mice deficient in their 
ability to respond to endotoxin, an IFN inducer. Induction of 2 1 ,5 1 -A 
dependent endoribonuclease has also been observed in guinea pig perito-
neal ma-crophages treated with mouse IFN- 6 (68). The induction of 2 1 ,5 1-
0AS in the guinea pig system is age-related (67). Peritoneal macrophages 
from older guinea pigs have 17% less synthetase activity than those from 
young guinea pigs. 
Results from 2 1 ,5 1-0AS studies in the bovine system have been simi-
lar to those previously discussed. Georgia bovine kidney cells (GBK) 
treated with HuiFN responded with increased 2 1 ,5 1-0AS levels (64). GBK 
cells did not respond as well as human HEp2 cells. The majority of 
bovine 2 1 ,5 1-0AS activity occurred in the nucleus as opposed to cyto-
plasmic activity in HEp2 cells (64). 
In vitro cultures of lymphocytes from calves previously administered 
HuiFN-a2 im and then challenged with vaccinia virus, had elevated 2 1 ,5 1 -
0AS levels when treated in vitro with HuiFN-a2 (65). These calves were 
also protected against vaccinia infection. In the same report, 2 1 ,5 1 -
OAS was induced in vivo in lymphocytes of calves treated with IFN and 
infected with BHV-1. Short and Fulton (57) reported in vitro and in 
vivo studies Which indicated increased 2 1 ,5 1-0AS activity in MDBK cells 
treated with BoiFN and PBML of cattle injected with BoiFN-ail or modi-
fied live virus vaccine (BHV-1, BVD, PI-3V). The increase in 2 1 ,5 1-0AS 
activity was reported to be proportional to both the concentration of 
IFN in the cell culture medium of the MDBK cells and the amount of cell-
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ular extract assayed. Elevated 2',5'-0AS activity, in PBML of the cattle 
inoculated with BHV-1/BVD/PI-3 modified live virus vaccine, persisted at 
least three days postvaccination. Enzyme levels in cattle injected with 
BoiFN reacted in a similar manner. Most bovine studies on the 2',5'-0AS 
system deal with the classical mechanism of 2',5'-0AS activity involving 
blockage of RNA viral protein synthesis. ·However, one in vitro study 
using bovine turbinate (BTu) cells pretreated with HuiFN-a2a and chal-
lenged with PI~3V reported virus yield reduction without complete block-
age of viral protein synthesis (44). That report suggested that the 
HuiFN-a2a affects glycoprotein synthesis and morphogenesis of PI-3V and, 
as a result, the antiviral state inhibited release of viral particles 
from the IFN treated cells. 
2',5'-0AS activity has also been related to growth rate, cell 
differentiation, and phagocytic activity (36,39,40, 60). Sub con f1 uent 
densities of murine JLS-V9R cells were grown to a confluent, stationary 
phase. Cell growth rate was inhibited after reaching confluency at 50 h 
and cell d iv is ion ceased after 100 h in culture. An increase in 2 ' , 5 '-
OAS between 50 and 100 h coincided with a substantial decrease in ~­
thymidine incorporation into cellular DNA (61). 
Undifferentiated (embryonal carcinoma) and differentiated (terato-
carcinoma) cells differed in sensitivity to IFN-inhibition of cell 
growth (60). IFN had little or no effect on the growth of undifferenti-
ated cells, but growth of differentiated cells was significantly inhib-
ited. Embryonal care inoma cells were also resistant to the antiviral 
activity of IFN when challenged with VSV, EMCV, and SBV. In contrast, 
IFN treated teratocarcinoma cells were protected against these viruses 
(60). Levels of 2',5'-A dependent endoribonuclease correlated with IFN 
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sensitivity in the two cell types (60). The IFN-sensitive teratocarci-
noma cells contained greater amounts of the nuclease. Krause et al. (36) 
also found expression of 2 1 ,5 1 -A dependent endoribonuclease to be great-
ly enhanced during cell differentiation. 
Innnunomodulatory effects of 2 1 ,5 1 -A have been reported in macro-
phages of rabbits, mice, guinea pigs, and humans (40). These macrophages 
were treated with various concentrations of 2 1 ,5 1 -A and then allowed to 
phagocytose Candida albicans. Increased phagocytic activity was observed 
in the macrophages from each species tested (40). 
RESEARCH OBJECTIVES 
IFNs are currently being investigated for prophylactic and thera-
peutic use in BRD. The effects of IFN on BAM have been reported. How-
ever, the mechanism of IFN action responsible for viral yield reduction 
and other functional alterations of BAM has not been completely 
resolved. Recent investigations have shown monitoring of 2 1 ,5 1 -OAS 
activity to be useful as a marker for response to IFN and acute viral 
infections. The purpose of this study was: (1) to determine the relia-
bility of monitoring 2 1 ,5 1-0AS activity of BAM (in culture and in vivo) 
as a marker for IFN induction; and (2) to determine a possible mechanism 
of IFN action responsible for viral yield reduction and other functional 
changes in BAMs. 
1. 
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CHAPTER II 
2',5'-0LIGOADENYLATE SYNTHETASE INDUCTION AND 
VIRUS YIELD REDUCTION IN RECOMBINANT DNA-
DERIVED BOVINE INTERFERON ALPHA-II 
TREATED BOVINE ALVEOLAR 
MACRO PHAGES 
The biological response of recombinant DNA-derived bovine inter-
feron alpha (BoiFN-ail) on bovine alveolar macrophages (BAM) was exam-
ined by measuring viral yield reduction and 2',5'-oligoadenylate synthe-
tase (2',5'-0AS) production by these IFN treated cells. IFN pretreatment 
of BAM reduced viral yield in parainfluenza-3 virus (PI-3V) challenged 
cultures compared to controls. Treatment of BAM with IFN also resulted 
in increased 2',5'-0AS activity. The increased 2',5'-0AS activity indi-
cates a possible mechanism of IFN action in the bovine system that may 
be responsible for viral yield reduction and other functional changes in 
BAM. 
INTRODUCTION 
Bovine respiratory diseases (BRD) are a major concern of the cattle 
industry due to the economic impact on the producer (20). The multifac-
torial etiology of BRD involves complex interactions between stressors 
and viruses acting separately or together. Viruses are responsible for a 
combination of activities affecting the antibacterial defense mechanisms 
24 
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of the lung: impairment of mucocillary clearance; suppression of phago-
cytic cell function; and interference with lymphocyte function, The 
result being suppression of lung defense mechanisms which leads to pre-
disposition to bacterial pneumonia (2 7). The enhancement of bacterial 
growth due to viral infection emphasizes the need for controlling both 
bacteria and viruses. One substance that has potent~al for controlling 
viruses and enhancing other bovine defense mechanisms (immunomodulation) 
in BRD is interferon (IFN). 
IFNs are (glyco)proteins induced in a cell by viral infection, 
double-stranded RNA, or other IFN-inducing agents. There are three types 
of interferon, alpha (a), beta (6), and gamma (Y), varying in their site 
of production and physicochemical and antigenic characteristics. IFNs 
are responsible for antiproliferative, antiviral, and immunomodulatory 
effects on cells. Excellent reviews of interferons (5, 15) describing 
their properties, actions, and potential prophylactic/therapeutic value 
are available. Antiviral effects of bovine and other homologous IFNs 
have been reported against different viral families (11,12,14). Studies 
have also been conducted on the innnunomodulatory effects of bovine and 
other homologous IFNs on their respective species ( 6, 22, 23, 35). Recent 
attention on the use of rBoiFN-a.I1 as a prophylactic agent for BRD has 
mainly focused on its antiviral effects. 
The antiviral activity of IFN includes the induction of an increase 
in two enzymes, 2 1 ,5 1 oligoadenylate synthetase (2', 5 1-0AS) and protein 
kinase. All three types of IFN are capable of inducing the enzyme 2 1 ,5 1 -
0AS discovered by Kerr et al. (16). 2 1 ,5 1-0AS synthesizes 2',5 1-oligo-
adenylates (2 1 ,5'-A) that activates a 2 1 ,5 1 -A dependent RNase which 
degrades mRNA and rRNA, thus inhibiting virus growth (8). The enzyme 
26 
2',5'-0AS has been suggested for use as a marker of IFN action (7,21,30, 
31,32,33,36,38) and viral infection (28,29,31). Merritt et al. reported 
increased 2 1 ,5'-0AS activity in human peripheral mononuclear cells after 
injection of IFN into healthy individuals and patients (21). Increased 
2 1 ,5 1 -OAS activity was also observed in mouse peripheral blood mononu-
clear cells (PBMC) following ip injection of either vesicular stomatitis 
virus (VSV) or Simbis virus (SBV) (29). Increased 2',5'-0AS activity has 
also been observed in macrophages treated with IFN in vitro (36,37). 
Decreased activity of 2',5'-0AS in macrophages has also been related to 
loss of the antiviral state (26) and increased susceptibility to virus 
infection (13,34). Vogel and Fertsch reported macrophages from C3H/HeJ 
mouse strain, bearing an autosomal gene defect diminishing their ability 
to respond to endotoxin, were more permissive to VSV infection and 
exhibited low basal concentrations of 2',5'-0AS as compared to non-
permissive fully endotoxin responsive mice (34). Gresser demonstrated an 
inverse correlation between the concentration of 2 1 ,5 '-OAS and permis-
siveness for VSV infection in peritoneal macrophages of mice injected 
with antibody to mouse IFN alpha/beta (13). In addition to the classical 
antiviral mechanism of 2 1 ,5'-0AS, 2' ,5'-A has been associated with 
increased phagocytosis in macrophages (18,19). 
Prior studies on 2',5'-0AS as related to IFN and the antiviral 
state have mainly focused on humans and murine species. Recent studies 
on the characterization of 2',5'-0AS in the bovine system (31,32,33) 
have provided new means of studying the IFN response in cattle. Periph-
eral blood mononuclear leukocytes (PBML) of calves inoculated with IBR/ 
BVD/PI-3V modified live virus vaccine and from calves injected with IFN 
have shown increased 2 1 ,5 1 -0AS activity (31). Many studies have been 
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performed on functional alterations of BAMs due to IFN (1,2,3,4); how-
ever, the mechanism of IFN action on the BAMs has not been completely 
resolved. The BAMs are considered to be important in primary cellular 
defense against extraneous microorganisms (5) such as those involved in 
BRD; therefore, it would be advantageous to understand the mechanism of 
IFN action on BAM. In the present study, we measured the biological 
response of BAM to rBoiFN-ail by viral yield reduction and increased 
2', 5 '-OAS activity. 
MATERIALS AND METHODS 
Animals. Three crossbred calves, weighing approximately 475 kg 
each, were purchased from commercial sources and were used as BAM 
donors. The calves were maintained on free choice hay with grain supple-
ment. 
Collection and maintenance ~ BAM. BAM were collected by broncho-
pulmonary lavage as described by Corstvet et al. (9). The lavaged cells 
were filtered through four layers of sterile gauze and centrifuged at 
250 x g at 10 °C for 10 min. The supernate was dis carded and pellets 
resuspended in cold (40°C) Tris-buffered ammonium chloride (0.16 M NH4Cl 
and 0.17 M Tris-HCl pH 7.65) to lyse contaminating RBC. The BAM were 
washed twice with IX Modified Hanks Balanced Salt Solution (HBSS) with-
out calcium, magnesium, and phenol red. Washed cells were resuspended in 
maintenance media consisting of RPM! 1640 (Gibco) without phenol red, 
with 20% fetal bovine serum (FBS), and SO ug/ml gentamicin. BAM were 
seeded in 15 ml conical polystyrene centrifuge tubes for use in yield 
reduction and 2' ,5'-0AS studies. Non-specific esterase stain (17) and 
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cellular morphology were used to identify BAM as the predominate cell 
type. 
Virus. PI-3V was grown in Madin Darby bovine kidney cells (MDBK), 
and titered by 24-well plate plaque assay on MDBK cells (10). 
Interferon. IFN used in this study was recombinant DNA-derived 
BoiFN- 11 (Ciba-Geigy). IFN titer (4.142 x 108 U/ml) was determined by 
24-well plate plaque reduction on MDBK monolayers challenged with VSV 
( 10). 
Yield reduction for antiviral activity. In three separate experi-
ments, BAM were collected from the three animals and were seeded in 0.1 
ml volumes in 15 ml conical polystyrene centrifuge tubes· (5 x 105 cells/ 
tube). The BAM were incubated for 3 h at 37 °C in 5% co2, and then pre-
treated with 10,000 IFN units for 8 h under incubation conditions 
previously described. Control cultures not receiving IFN but infected 
with PI-3V were also included. After 8 h pretreatment with IFN, PI-3V 
was added at a M. 0. I. of 0. 1 and infected cells were then incubated 24 h 
under previously described conditions. Samples were frozen at -70 °C 
until viral infectivity was measured by 24-well plaque assay on MDBK 
monolayers as described previously (10). Viral yields were expressed as 
PFU/0. 1 ml. 
Cell extracts. 2',5'-0AS activity was measured in BAM concurrently 
with the yield reduction experiments. BAM (1 x 10 6 cells in 0. 2 ml 
maintenance media) were seeded in 15 ml polystyrene conical centrifuge 
tubes and incubated 3 hours at 37°C in 5% co 2, and then pretreated with 
10,000 IFN units under the same incubation conditions. Untreated control 
BAM cultures were also included in this experiment. At 0 h, 8 h, and 32 
h post treatment, samples were processed for assay of 2',5'-0AS activ-
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ity. Cells were washed once with PBS by centrifugation at 1000 x g for 1 
min. The supernatants were removed and cells were then lysed by suspen-
sion in buffer containing the detergent Nonidet P-40 as described by 
Schattner et al. (29). After lysis buffer was added, cells were frozen 
at -70°C until further processing. Cells were thawed at 25°C and allowed 
to stand for 30 min at 4°C. Cell lysates were then transferred to poly-
propylene microcentrifuge tubes and centrifuged at 12,000 x g for 6 min. 
The cell extract (CE) was removed immediately for use in the enzyme 
assay. 
Activity~ 2',5'-oligo(A)synthetase. Enzyme activity was measured 
by using a modification by Short and Fulton (31) of the 2',5'-0AS assay 
described by Schattner et al. (29). [8-14c] ATP as the substrate instead 
of [a-32P]. Cell extracts and reaction mixture were incubated 18 h, 
digested with alkaline phosphatase, and then 25 ul of distilled water 
was added to each sample prior to freezing at -l0°C. Samples were thawed 
at room temperature and then loaded onto Dowex 1 (Cl-) columns. Columns 
were eluted with 2ml of distilled water and the eluate was collected 
directly into scintillation vials. Columns were next eluted with 2ml of 
0. 01 M HCl-1. 0 M NaCl which was collected into separate scintillation 
vials. All eluates were mixed with 15 ml of Scinti-Verse (Fisher Scien-
tific Co.) for counting in a Pakard Tri-Carb 300 scintillation counter 
(Canberra Co., Laguna Hills, CA). 
RESULTS 
The pretreated BAM (10,000 units of BoiFN-ail 8 h prior to chal-
lenge exposure with PI-3V at M.O.I. of 0.1), had significantly (P < 
0.001) greater viral yield reductions than BAM not receiving IFN 
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(Table 1). Viral yield reductions (Log 10 PFU/0.1 ml culture fluid) were 
1.5, 0.6, and 1.1 for each animal, respectively. Although the sensitiv-
ity varied for the same animals between experiments and among animals on 
the same experiment, IFN treated macrophages showed consistent yield 
reductions compared with their control BAM. Elevated 2',5'-0AS activity 
was also observed in the IFN treated (P < 0. 05) BAM as compared with 
untreated BAM (Fig. 1). 2',5'-0AS activity increased 80% ± 39% at the 8 
h time point and 174% ± 89% at the 32 h time point in IFN treated BAM as 
compared to 16% ± 27% and 35% ± 31% 1n untreated BAM at 8 h and 32 h 
time points respectively. A temporal relationship occurred between 
percent viral yield reduction and percent increase in 2',4'-0AS activity 
in rBo IFN-Cll1 treated BAM. 
DISCUSSION 
Several previous studies have shown decreased viral susceptibility 
(4,13,34) and altered macrophage functions (4,23,35) due to IFN. How-
ever, these studies did not address relationships between the changes in 
susceptibility and function with respect to possible molecular mechan-
isms of IFN action in the bovine system. In the present study viral 
yield reduction was observed in IFN treated BAM challenged in vitro with 
PI-3V. 2' ,5'-0AS levels also increased in BAM treated with IFN. These 
results suggest that 2',5'-0AS may be important in the mechanism of IFN 
action during the antiviral state in BAMs. The mechanism may be due to 
either the classical 2',5'-A dependent endoribonuclease cleavage of RNA 
or by other products of 2',5'-0AS activity. These findings are similar 
to those of Wang and Wu (35) in which IFN induced de novo synthesis of 
2' ,5'-A dependent endoribonuclease activity in cultured guinea pig 
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macrophages, and Gresser et al. (13) who reported a correlation between 
levels of 2' ,5'-0AS in mouse peritoneal macrophages and the permissive-
ness of the cells for VSV. A recent study by Panigrahi et al. (24) 
suggested that the classical mechanism of 2' ,5'-A activated endonuclease 
and protein kinase seemed unimportant in the inhibited production of 
infectious PI-3V in HuiFN-0.2a t;reated bovine turbinate cells. However, 
2',5'-0AS levels were not measured in their study, instead, production 
of viral proteins was compared in IFN-treated and nontreated cells (24). 
Although total inhibition of viral proteins was not observed in their 
system (24), this does not rule out the possibility that 2',5'-0AS or 
its products were involved in inhibition of PI-3V. Incomplete blockage 
of viral protein synthesis could be due to varied sensitivity of viral 
RNA to the 2' ,5'-A dependent endoribonuclease or other products of the 
2', 5 '-OAS system. Even if the classical mechanism of 2' ,5 '-A dependent 
endoribonuclease is not involved in the antiviral state in the BAM, 
functional alterations of macrophages by 2' ,5'-A (18) suggests the 
involvement of 2',5'-0AS in the mechanism of IFN action in the bovine 
system to be important. 
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Table 1. Effect of bovine IFN on PI-3'V replication in bovine alveolar 
macro phages 
Virus Yielda 
Virus IFN Percent (%) 
Animal if Experiment if control treated reduction 
07 1 1.9 X 103 3.5 X 101 
2 2.8 X 103 1.0 X 102 97 + 1 
3 3.9 X 10 2 1.5 X 10 1 
11 1 1.5 X 102 4.0 X 101 
2 1.4 X 102 6.5 X 101 73 + 19 
3 1.9 X 102 1.5 X 101 
19 1 8.0 X 102 1.5 X 101 
2 1.5 X 102 6.0 X 101 82 + 19 
3 1.3 X 102 1.5 X 101 
avirus yields are expressed as PFU per 0.1 ml of culture fluids. All 
culture fluids were from 24 h viral postchallenge collections. 
bPercent (%) reduction is the average± SD of% viral yield reduc-
tions for each of the 3 experiments. 
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Fig. 1. 
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IN ~ INDUCTION OF 2 I '5 I -OLIGOADENYLATE 
SYNTHETASE BY RECOMBINANT DNA-DERIVED 
BOVINE INTERFERON ALPHA-II IN 
BOVINE ALVEOLAR MACROPHAGES 
2 1 ,5 1-oligoadenylate synthetase (2 1 ,5 1 -0AS) activity was measured 
in bovine alveolar macro phages (BAM) and peripheral blood mononuclear 
leukocytes (PBML) of calves injected intramuscularly (im) with 3.6 x 106 
U/kg of recombinant DNA-derived bovine alpha interferon (BoiFN-ail). 
The PBML were used to monitor IFN action by measuring 2 1 ,5 1 -0AS activity 
beginning six days prior to and 24 h after IFN treatment. 2 1 ,5 1-0AS 
activity in the PBML sharply increased 24 h after IFN treatment indicat-
ing response to IFN. BAM collected from the same calves 24 h after IFN 
injection also had increased 2 1 ,5 1 -0AS activity as compared to BAM of 
the same calves collected 6 days prior to treatment. The change in 
2 1 , 1 5-0AS activity in BAM suggests the possibility of using the enzyme 
as a marker for IFN induction 1.n future experiments involving IFN and 
its effects on macrophages and the bovine immune system. 
IN TROD UC TI ON 
Interferons are (glyco)proteins produced in virus infected cells or 
by other inducers. There are three types of IFN, alpha (a), beta ([:3), 
and (y), which differ in their site of production and in their physico-
40 
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chemical and antigenic characteristics. The effects of IFN on cells are 
antiproliferative, immunomodulating, and antiviral. The antiviral state 
involves two enzymes, 2 1,5 1 -OAS and protein kinase, induced by inter-
feron. Both the human and bovine interferon systems have been extensive-
ly reviewed (3, 11). 
All three types of IFN are capable of inducing the enzyme 2 1,5 1-0AS 
which was discovered by Kerr et al. (12). 2 1,5 1-0AS synthesizes 2 1,5 1-
oligoadenylates (2 1,5 1-A) which activate a 2 1,5 1-A dependent endoribo-
nuclease (5). The 2 1,5 1-A dependent endoribonuclease degrades virus and 
cellular RNA thus inhibiting protein and DNA synthesis resulting ~n 
virus growth inhibition (5). Proietti et al. (18) found that decreased 
levels of 2 1,5 1-0AS in aged mouse peritoneal macrophages paralleled the 
loss of the antiviral state. Other functional changes in cells have 
also been attributed to 2 1,5 1-A (13,14). Liu et al. (14) reported 
increased phagocytic activity of rabbit, mouse, guinea pig, and human 
macro phages due to treatment with 2 1,5 1-01 igo( A). 2 1,5 1-0AS has been 
considered for use as a marker of IFN action (4,15,16,20-25). Witter et 
al. ( 25) showed a dose-response relationship between recombinant human 
IFN- 2a dose and both 2 1,5 1-0AS activity and vesicular stomatitis v~rus 
resistance in humans. 
Interferon and its effects on many bovine viruses has been investi-
gated (2,7-9,11). Recent characterization of 2 1,5 1-0AS in the bovine 
system should aid in studying the response of the bovine system to IFN 
(22,23). Short and Fulton (21) observed increased levels of 2 1,5 1-0AS 
in PBML of calves treated with IFN and in calves administered BHV-1/BVD/ 
PI -3V modified 1 ive virus vaccine (MLV). Their results suggest 21,51-
OAS can be used as a marker for IFN induction as is the case in humans. 
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Due to the emphasis on the potential of IFN use as a prophylatic in 
bovine respiratory disease (BRD), the measurement of 2 1 ,5 1-0AS levels 
may be helpful in understanding the response to IFN, and possibly as a 
marker indicating acute viral infection (19,21). 
BAM are important in primary defense of the lung against invasion 
of microorganisms as in BRD (3). The in vivo effects of IFN on 2 1 ,5 1 -
OAS induction in BAM have not been studied to date; therefore, the 
present study measured the in vivo response of BAM to im injection of 
rBoiFN-ar 1 by measuring 2 1 ,5 1 -0AS activity in these cells. 
MATERIAlS AND METHODS 
Animals. Crossbred calves, weighing 475 ± 19 kg each, were 
purchased from connnercial sources and were used as BAM donors. The 
calves were maintained on free choice hay with grain supplement. 
Collection and maintenance of BAM. BAM were collected by broncho-
pulmonary lavage as described by Corstvet et al. (6). The lavaged cells 
were filtered through four layers of sterile gauze and centrifuged 10 
min at 250 x g at 10 °C. The supernatant was discarded and pellets re-
suspended in cold (4 °C) Tris-buffered annnonium chloride (0.16 m NH4Cl 
and 0.17 M Tris adjusted to pH to 7. 2 with HCl) to lyse contaminating 
erythrocytes. The BAM were washed twice with 1X Modified Hanks Balanced 
Salt Solution (HBSS) without calcium, magnesium, and phenol red. Washed 
cells were resuspended in maintenance media consisting of RPMI 1640 
(Gibco) without phenol red, with 20% fet"al bovine serum (FBS) ,and 50 
ug/ ml gentamicin. Cell counts and viability were calculated using a 
hemocytometer and trypan blue exclusion. 
Interferon. The IFN used in this experiment was recombinant DNA-
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derived BoiFN-all (Ciba-Geigy). The IFN titers (4.142 x 108 U/ml) was 
determined by 24-well plate plaque reduction on Madin-Darby bovine 
kidney cell (MDBK) monolayers challenged with vesicular stomatitis virus 
vsv (7). 
Cell extracts. BAM from calves administered IFN im (3.6 x 10 6 
U/kg) and from a control calf not receiving IFN were collected and 
counted as previously described. BAM from all calves were also collected 
six days prior to IFN treatment to obtain the baseline levels of 2' ,5'-
0AS in the BAM. A six day interval was chosen due to adverse effects on 
the composition of the BAM population and cell activities when shorter 
intervals are used (1). Duplicate samples of 5 x 105 BAM from each calf 
and from both collection times were placed in microcentrifuge tubes. 
Cells were washed once with PBS, centrifuged at 1000 x g for 1 m1n. The 
cell pellets were resuspended in lysis buffer containing the detergent 
Nonidet P-40 as described by Schattner et al. (19) and then frozen at 
-70°C until further processing. Frozen lysates were thawed at 25°C and 
allowed to incubate at 4 °C for 30 min to complete the lysis. Lysates 
were then centrifuged at 12,000 x g for 6 min to remove cell debris. 
The cell extracts were removed immediately for use in the enzyme assay. 
PBML were collected using Sepracell-MN (Sepratech Company, Oklahoma 
City, OK). Four ml of heparinized whole blood were added to 5. 5 ml of 
Sepracell-MN and centrifuged at 1600 x g for 10 min in an IEC table top 
centrifuge with a fixed angle rotor. The top 2. 5 ml were removed and 
added to 15 ml conical polystyrene tubes and washed 2X with PBS for 1 
min at 1500 x g. Cells were resuspended in PBS and counted on a hemocy-
tometer. PBML (1 x 10 6 cells in 0.2 ml maintenance media) were added to 
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microcentrifuge tubes and processed as described above for use in 2 1 ,5 1 -
0AS assay. 
Activity of 2 1 ,5 1-0AS. Enzyme activity was measured us~ng a modifi-
cation by Short and Fulton (21) of the 2 1 ,5 1 -OAS assay system of Schat-
tner et al. (19) using [8-14c]ATP as the substrate in the reaction 
mixture. 2 1 ,5 1 -OAS was purified by mixing cell extract with agarose 
poly(I):poly(C) beads and washing with buffer. Reaction mixture and 
washed beads were combined and incubated at 30 °C for 18 h. Alkaline 
phosphate was then added, temperature was increased to 37°C, and incuba-
tion was continued for 1 h. After addition of 25 ml of distilled water, 
all samples were frozen at -l0°C until further processing. Thawed samp-
les were run on Dowex 1 (Cl-) coltmlns. Coltmlns were eluted with 2 ml 
dH 20 followed by 2 ml 0.01 M HCl-lM NaCl. Water and acid eluates were 
collected in separate scintillation vials and mixed with 15 ml of 
Scinti-Verse (Fisher Scientific) for counting in a Pakard Tri-Carb 300 
counter (Canberra Company, Laguna Hills, CA). 
RESULTS 
2 1 ,5 1-0AS activity in bovine PBML was monitored beginning six days 
before and 24 h after treatment with 3.6 x 10 6 U/kg of rBoiFN-ail (Fig. 
1). Baseline 2 1 ,5 1 -0AS activity of 320 ± 131 pmols/h/106 cells in PBML 
from the untreated control calf remained constant for the duration of 
the experiment. Enzyme activity was 460 ± 134 pmol s/h/ 10 6 ce 11 s in the 
treatment group (n = 3) prior to IFN treatment. 2 1 ,5 1 -0AS activity of 
PBML increased to 2133 ± 234 pmol s/h/106 cells on day 1 (24 h post-
treatment) in animals receiving IFN. BAM collected on days -6 and 1 
produced 2 1 ,5 1-0AS activity similar in response to IFN as the PBML. 
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BAMs were collected twice at a 6 day interval due to a report of adverse 
affects on the composition of the BAM population or cell activities when 
shorter intervals are used (1). Incorporation of [s-14c) adenyl ate into 
2',5'-0AS by CE of BAM from untreated animals (n = 5) was 3180:!: 926 
pmols/h/10 6 cells. Corresponding activity 2',5'-0AS by CE of BAM from 
treated animals (n = 3) was 5060 ± 141 pmols/h/10 6 cells (P < 0.05) 
(Fig. 2). 
DISCUSSION 
Interferon has been shown to inhibit many bovine viruses (2, 7-9, 
11). In addition to its antiviral effects in the bovine system, IFN has 
other effects on bovine cells including enhanced bacterial phagocytosis 
and antibody dependent cell-mediated cytotoxicity ( ADCC) in macrophages, 
blood monocytes, and polymorphonuclear cells (3). IFN is currently being 
considered for use as a prophylactic agent for BRD. Recent studies of 
the 2',5'-0AS system in cattle (21,22,23) suggests its potential use as 
a marker in the bovine for IFN action as demonstrated in humans (20) and 
in murine species (10). Short and Fulton (21) found increased 2',5'-0AS 
levels in PBML of cattle inoculated with modified live virus vaccine and 
cattle treated with IFN. The study not only supports the use of 2',5'-
0AS as a marker for IFN action in the bovine system, but also suggests 
the possibility of monitoring virus infection. 
Since BAM are important in defense against microorganisms invading 
the lu~s (3), this study measured the response of BAM from IFN treated 
cattle by measuring 2',5'-0AS activity in these cells. PBML from the 
same animals were also collected at the same time and at points in 
between the BAM collections. 2',5'-0AS levels were also measured in the 
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PBML. 2',5'-0AS activity increased in BAM of calves treated im with 
rBo!FN-di 1 as compared with levels in BAM collected 6 days prior to IFN 
treatment from the same calves. 2'5'-0AS levels also increased in PBML 
of these same calves used for BAM source. These results are similar to 
those of Short and Fulton as described above (21). 2'5'-0AS activity in 
both PBML and BAM increased following IFN injection; however, basal 
activities varied between these two cell types with BAM having the 
greater activity. Variation in basal activity of 2' ,5'-0AS in different 
cell types has also been reported in studies of human peripheral white 
blood cells (20). 
The results of this study suggest that BAM of calves treated with 
IFN do respond by increasing 2',5'-0AS activity. Whether or not the 
increased 2', 5'-0AS activity is involved in the mechanism of IFN action 
responsible for the antiviral state or other functional alterations of 
IFN treated BAM remains to be determined. 
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Fig. 1. Effect of intramuscular injection of IFN on PBML 
2',5'-oligoadenylate synthetase activity. CE was prepared from 
PBML of an untreated control calf ( e ) and IFN treated cattle 
( • ). The results presented are the mean± SD n = 1 for 
untreated calf and n = 3 for IFN treated calves. 
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Fig. 2. Effect of intramuscular injection of IFN on BAM 
2',5'-oligoadenylate synthetase activity. CE was prepared from 
BAM of untreated control cattle and IFN treated cattle. The 
results presented are the mean ± SD n = 5 for untreated cattle 
and n = 3 for IFN treated cattle. 
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CHAPrER IV 
SUMMARY AND CONCLUSIONS 
The purpose of this study was to measure the biological response of 
bovine alveolar macrophages (BAM) to recombinant DNA-derived bovine 
interferon alpha-I1 (rBoiFN-ai1). The in vitro response was monitored 
by two parameters: 1) yield reduction of PI-3V and 2) 2 1 ,5'-oligoadeny-
late synthetase (2 1 ,5 1-0AS) activity in IFN treated and untreated BAM 
cultures. To confirm our in vitro findings by in vivo studies, we mon1-
tored 2 1 ,5'-0AS activity in BAM of calves treated with rBoiFN-ail. 
Viral yields in PI-3V challenged, IFN treated BAM were significant-
ly (P < 0. 001) reduced as compared to untreated, PI-3V challenged BAM. 
The average percent viral yield reduction was 84% and the standard devi-
ation was± 17% (n = 9). 2',5 1-0AS activity in IFN treated BAM increased 
80% :!: 39% at the 8 h time point and 174% :!: ~9% at the 32 h time point 
compared to 16% :!: 27% and 35% :!: 31% at the respective time points in 
untreated BAM. BAM of individual animals showed varying increases in 
2 1 ,5'-0AS activity. There seems to be a temporal relation between 
increased 2', 5 1-0AS activity and viral yield reduction in vitro in BAM. 
Calves which received 3. 6 x 10 6 U/kg of rBoiFN-ai1 showed a significant 
(P < 0.05) elevation of 2',5'-0AS activity in their .BAM compared to the 
enzyme activity in their BAM collected prior to IFN administration. 
BAM isolated from all three animals in the in vitro study had 
increased 2 1 ,5 1-0AS activity and decreased viral yields following treat-
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ment with IFN. Although the response pattern was similar for all three 
calves, the magnitude of the response varied. 2' ,5'-0AS activity also 
varied in the in vivo experiment, especially in BAM collected prior to 
IFN injection. The variation in BAM enzyme activity of untreated calves 
in the in vivo experiment suggest more studies should be conducted to 
better establish the in vivo baseline 2' ,5'-0AS activity in BAM. Any 
future studies should use larger sample populations for a better esti-
mate of baseline activity. Varied baseline levels and responses of 
2',5'-0AS activity have also been reported in studies on humans (3,4). 
The results of this study are consistent with those reported for 
the murine and human systems. Previous studies have indicated decreased 
susceptibility of BAM due to the effects of IFN (1,2,6). Wang and Wu (7) 
reported IFN induced de~ synthesis of 2', 5 '-oligoadenylate (2', 5 '-A) 
dependent endoribonuclease in cultured guinea pig macrophages. 2 I' 5 '-A 
dependent endoribonuclease is ari RNase which degrades mRNA and rRNA, 
thus inhibiting virus replication. Gresser et al. (2) reported correla-
tion between levels of 2', 5 '-OAS activity in mouse peritoneal macro-
phages and the permissiveness of these cells for vesicular stomatitis 
virus. In vivo induction of 2', 5 '-OAS activity in bovine peripheral 
blood mononuclear leukocytes (PBML) have been reported in response to 
exogenous treatment with rBoiFN-a Il and in response to modified live 
virus vaccine ( 5) . However, there are no reports on the biological 
effects of IFN on BAM, as related to the 2' ,5'-0AS system. 
Indue tion of 2', 5 '-OAS activity in recombinant IFN treated BAM 
supports the use of 2',5'-0AS as a marker for IFN induction. The 
temporal relationship between viral yield reduction and increased 2',5'-
OAS activity in IFN treated BAM suggests involvement of 2',5'-0AS in the 
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action of IFN induction of the antiviral state observed in these cells. 
The above findings will be beneficial in future studies on the mechanism 
by which IFN increases antiviral properties in BAM and monitoring 
responses to IFN in bovine respiratory disease (BRD) trials. The ability 
of individual calves to initiate a 2',5'-0AS response may be recognized 
in future experiments as important in their ability to withstand infec-
tions as in BRD. 
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